Stryker (NYSE:SYK) misses Q3 2026 sales expectations, stock drops
Stryker (SYK) reported Q3 2026 revenue of $6.52B, up 7.6% YoY but below expectations. Non-GAAP EPS of $3.52 missed estimates by 0.8%. CEO Kevin Lobo stated fundamentals remain strong, expecting solid Q4 performance. Analysts project 9.7% revenue growth over the next 12 months, with EPS expected to grow 14.7%. Shares dropped 8.5% post-earnings.
How this was made
The 30-second read
Why it matters
The key tradable elements are the revenue miss versus consensus, the near-consensus adjusted EPS, and the margin contraction that likely drove the immediate selloff. Management’s guidance language points to stabilization in Q4 and momentum into 2027, which may support dip-buying if investors believe the margin issue is transitory.
Market read
Company-specific earnings reaction with concrete figures (revenue, adjusted EPS, margin) and an immediate stock move, making it relevant for near-term positioning in medtech.
What to watch
The article highlights a sharp adjusted operating margin contraction (down 9.7 percentage points YoY) but does not explain the drivers; traders may need to wait for segment or cost-detail disclosures to judge whether this is temporary.
Background
Stryker reported Q3 2026 results with revenue growth but a shortfall versus Wall Street expectations, alongside a notable decline in adjusted operating margin.
Ticker impact
Stryker missed Q3 2026 revenue expectations, with revenue up 7.6% to $6.52B but adjusted EPS $3.52 slightly below consensus, sending shares down 8.5%.
Likely continued pressure or elevated volatility as traders weigh the revenue shortfall and adjusted operating margin drop versus management’s Q4 and 2027 momentum commentary.
The article reports a same-day stock drop tied to the company’s own Q3 results, including a revenue miss and a large year-over-year adjusted operating margin contraction (15.9% vs prior year).
Market effects
Reinforces that even high-quality medtech names can see multiple compression when revenue misses and margins contract, potentially raising scrutiny on healthcare demand durability.
Primarily US large-cap healthcare sentiment, with limited direct spillover beyond medtech earnings season positioning.
Low global spillover; the story is company-specific rather than a cross-market macro or regulatory shift.
Counterpoint
The miss is framed as falling short of expectations despite 7.7% organic sales growth and double-digit adjusted earnings growth, suggesting the market may be over-penalizing relative to fundamentals.
Key entities
- companyStryker
Medical technology company reporting Q3 2026 revenue and adjusted EPS, with shares dropping after the results.
